HAEM5:Volunteer Assignments and Opportunities: Difference between revisions
| [checked revision] | [checked revision] |
No edit summary |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 293: | Line 293: | ||
|7/1/24 | |7/1/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|Jennelle Hodge (JH)/ Malini Sathanoori (MS) | |Jennelle Hodge (JH)/ Malini Sathanoori (MS) | ||
| Line 406: | Line 406: | ||
|7/1/24 | |7/1/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 419: | Line 419: | ||
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | |[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]] | ||
|Disease | |Disease | ||
| | |Gordana Raca MD PhD, | ||
|9/8/25 | |||
| | |||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 438: | Line 438: | ||
|12/20/23 | |12/20/23 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 458: | Line 458: | ||
|JH_MS | |JH_MS | ||
| | | | ||
|Open to new author | |emailed request on 7/16/24. No response as of 9/7/25. | ||
Prior author: Xinjie Xu, PhD, FACMG | |||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Mutated NPM1 | |Acute Myeloid Leukemia (AML) with Mutated NPM1 | ||
|Xinjie Xu, PhD, FACMG | |Xinjie Xu, PhD, FACMG | ||
| Line 483: | Line 486: | ||
|[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | |[[HAEM5:Acute myeloid leukaemia, myelodysplasia-related|Acute myeloid leukaemia, myelodysplasia-related]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 490: | Line 493: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | |Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 522: | Line 525: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: Celeste Eno, PhD | ||
Open to new author | |||
|Acute Myeloid Leukemia (AML) with Minimal Differentiation | |Acute Myeloid Leukemia (AML) with Minimal Differentiation | ||
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | |Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles, Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine | ||
| Line 547: | Line 552: | ||
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | |[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 563: | Line 568: | ||
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | |[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]] | ||
|Disease | |Disease | ||
| | |Jennelle C. Hodge, PhD | ||
| | | | ||
| | | | ||
|Pending | |||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 582: | Line 587: | ||
|5/1/24 | |5/1/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 595: | Line 600: | ||
|[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | |[[HAEM5:Acute myelomonocytic leukaemia|Acute myelomonocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 602: | Line 607: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Myelomonocytic Leukemia | |Acute Myelomonocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 611: | Line 616: | ||
|[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | |[[HAEM5:Acute monocytic leukaemia|Acute monocytic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 618: | Line 623: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Monoblastic and Monocytic Leukemia | |Acute Monoblastic and Monocytic Leukemia | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 630: | Line 635: | ||
|5/1/24 | |5/1/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 643: | Line 648: | ||
|[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | |[[HAEM5:Acute megakaryoblastic leukaemia|Acute megakaryoblastic leukaemia]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 650: | Line 655: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25 | ||
|Acute Megakaryoblastic Leukemia (AMKL) | |Acute Megakaryoblastic Leukemia (AMKL) | ||
|Fei Yang, MD, FACMG <br> Oregon Health & Science University | |Fei Yang, MD, FACMG <br> Oregon Health & Science University | ||
| Line 662: | Line 667: | ||
|6/11/24 | |6/11/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 698: | Line 703: | ||
|7/1/24 | |7/1/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 730: | Line 735: | ||
|12/6/24 | |12/6/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 743: | Line 748: | ||
|[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | |[[HAEM5:Myeloid proliferations associated with Down syndrome|Myeloid proliferations associated with Down syndrome]] | ||
|Disease | |Disease | ||
| | | | ||
| | | | ||
| | | | ||
| Line 750: | Line 755: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |Prior author: | ||
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |||
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | |MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome | ||
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | |Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO | ||
| Line 942: | Line 948: | ||
|7/1/24 | |7/1/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 962: | Line 968: | ||
|JH_MS | |JH_MS | ||
| | | | ||
| | |emailed 5/1/24 | ||
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | |Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified | ||
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | |Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine | ||
| Line 974: | Line 980: | ||
|5/9/24 | |5/9/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||
| Line 1,007: | Line 1,013: | ||
|7/1/24 | |7/1/24 | ||
| | | | ||
| | |Pending | ||
| | | | ||
|JH_MS | |JH_MS | ||